SEC Form 6-K filed by ALPS Group Inc
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number: 001-42915
Alps Group Inc
(Registrant’s Name)
Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)
No. 1, Jalan 1/68F, Jalan Tun Razak
50400 Kuala Lumpur
Wilayah Persekutuan, Malaysia
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information Contained in this Form 6-K Report
Attached hereto as Exhibit 99.1 is a press release dated February 23, 2026 issued by Alps Group Inc relating to a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports that highlights the effectiveness of Autologous Immune Enhancement Therapy.
Exhibits
| Exhibit No. | Description | |
| 99.1* | Press Release dated February 23, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alps Group Inc | ||
| Date: February 23, 2026 | By: | /s/ Dr. Tham Seng Kong |
| Name: | Dr. Tham Seng Kong | |
| Title: | Chief Executive Officer and Director | |